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treatment of 16,035 patients in 2009 (7,150,000 CHF; new service) with 2007
(7,184,000 CHF; old service, adjusted to 16,035 patients) showed slightly reduced
costs (-34,000 CHF; 95%-CI:60,000 to -127,000).CONCLUSIONS:The cost reduction
of 0.5% is a conservative estimate as wages have increased since 2007. The reor-
ganisation has the potential to be a dominant intervention: While quality of service
provision improved, treatment costs slightly decreased against the secular trend of
increase. Data has to be confirmed in follow-up measurements for decision mak-
ers.
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OBJECTIVES: The Stability and Growth Pact approved by the Portuguese Govern-
ment in 2010 limits the expenditure growth in 1% for reimbursed pharmaceuticals
in outpatient sector. The Memorandum of Understanding signed in May 2011 be-
tween the Government and the International Authorities subsequently has in-
creased the requirements to reduce public expenditure. Considering the pricing
and reimbursement changes, this study aims to: 1) analyze public expenditure
trends on medicines, and 2) identify the main factors and impacts. METHODS: We
have analyzed the database sales and prescription data from Portuguese commu-
nity pharmacies, and performed simulations to measure the impact of policy mea-
sures. The statistical analysis of monthly data by product was performed with SAS.
RESULTS: The NHS expenditure in outpatient medicines has increased 5.6% in
2010. The legislation approved in June 2009, that established generics reimburse-
ment at 100% for some pensioners (withdrawn in June 2010), was responsible for
more 26.8 million euros of NHS spending in 2010. Nevertheless 117.1 million euros
were explained by new molecules reimbursed in the last three years. After July 2010
and due to the 1% VAT increase, the expenditure had increased 7.5 million euros.
The Health Subsystems (special security schemes for certain professions) had also
contributed positively: in December about 7.4 million euros were transferred from
the ‘ADSE’ (civil servants subsystem) for NHS. At the end of 2010, the Government
adopted further measures to control public expenditure, such as 6% prices deduc-
tion and several reductions in pharmaceuticals reimbursement levels. Immedi-
ately the NHS medicines expenditure decreased 21.2% in the four first months of
2011. In opposition the hospital market is growing 3.5%. CONCLUSIONS: Besides
price and reimbursement administrative reductions, with limited impact in the
short run, it would be important to consider measures, that should be assessed on
a periodic basis to identify the best strategies to promote rationality and efficiency
in the outpatient and hospital sector.
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OBJECTIVES: To compare the use of health care services between patients with
private and public drug insurance among users of anti-depressants. METHODS: A
matched retrospective cohort study was conducted using databases for Quebec
residents with private (reMed database) or public (RAMQ database) drug insurance.
The study included 194 reMed and 1923 RAMQ patients aged 18 to 64 years who
filled at least one prescription of an antidepressant between December 2007 and
September 2009. Patients were matched on age, sex and date of 1st filled prescrip-
tion of an antidepressant. The primary outcomes were the number of outpatients
medical visits, emergency department (ED) visit (yes/no) and hospitalization (yes/
no) for all causes over one year. The secondary outcome was the average antide-
pressant cost per patient per month. Linear or logistic regression was used to
compare the outcomes between patients with private and public drug insurance,
while adjusting for potential confounders. RESULTS: Patients with private drug
insurance (21.3% males) had 8.1 outpatient medical visits on average, 17.5% had an
ED visit and 8.8% were hospitalized over one year. Corresponding figures were 6.6,
20.0% and 8.5% for patients with public drug insurance (23.6% males). Patients with
private drug insurance were found to have more outpatient medical visits than
patients with public drug insurance (adjusted mean difference 1.2; 95%CI: 0.2 to
2.3), but were not more likely to have an ED visit (adjusted OR 0.7; 95% CI: 0.5 to 1.1)
or a hospitalization (OR0.9; 95%CI: 0.5-1.6). Average cost per patient per month for
antidepressants was $48.50 (95%CI: 44.97-52.02) and $33.73 (95%CI: 32.94-34.51) for
patients with private and public drug insurance, respectively. CONCLUSIONS: Lit-
tle differences were found in the use of health care services between users of
antidepressants with private and public drug insurance, while important differ-
ences were observed for the cost of antidepressants.
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OBJECTIVES: To explore the current status (2010) of tendering programs for outpa-
tient pharmaceuticals in the European countries and how these programs operate.
METHODS: A survey was designed to assess the features of tendering programs in
European countries. All 27 countries of the European Union plus Norway were
included in the study. The survey was sent to national representatives of authori-
ties and organizations and to academic researchers with expertise in the domain.
RESULTS: Nineteen of the 28 countries have responded to the questionnaire (68%).
Seven countries have adopted tendering programs for pharmaceuticals in ambu-
latory care. Tendering was more popular in countries with a mature generic med-
icines market (54%) than in countries with a developing generic medicines market
(12.5%). Authorities with financial interest for possible savings issued the tenders
and the lowest price/best offer was amongst the criteria to award the tender in
most cases. The frequency varied from only once to once every two weeks and the
number of winners was between one and four. The objectives of achieving cost
savings were achieved in the short term but results on long term are still unclear.
CONCLUSIONS: Tendering programs can achieve savings in the short term, but the
effects in the long term are still unclear. It can be concluded that the policy can
work, but the features of the programs such as the legal framework, the criteria to
grant the tender, the number of winners, the reward of the winner and the fre-
quency, have to be well-thought-out.
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OBJECTIVES: To assess the performance in seven homogenous specialty clinics
across all NHS hospitals in the Regional Health Authority of Thessaly (RHAT), over
the period 2002-2006. METHODS: Data Envelopment Analysis by using the
Malmquist Productivity Index and its decompositions have been applied in order to
measure the technical efficiency and productivity. Clinics were considered to
transform inputs labour (medical and nursing staff) and capital (hospital beds) into
health services, approximated by the number of in-patient discharges and in-pa-
tient days, used as outputs. The model is output oriented and assumes variable
return to scale. Data were collected from hospitals’ records. RESULTS: Overall pro-
ductivity progressed in all clinics, led by technical change rather than technical
efficiency. Over the whole period the size of the clinics influences the overall effects
on hospital performance and the maximum level of outputs produced has not been
achieved using the given labour and capital inputs, except orthopaedic clinics. The
highest productivity changes were achieved by the gynecology (22.5%), the urology
(15.7%) and the paediatric clinics (15.4%). All clinics experienced high technological
change level, except general medicine clinics which drops by 6.5%. The highest
technological changes were experienced by gynecology clinics (48.4%), the paedi-
atrics (26.2%) and ophthalmology (22.1%). CONCLUSIONS: Homogeneity in assess-
ing hospitals’ performance provides evidence on the efficiency and productivity
gains among clinics and suggests improvements in those which appear inefficient.
The difficult economic situation Greece is facing nowadays makes the assessment
of NHS hospitals’ performance a priority in the decision making.
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OBJECTIVES: Muscle relaxants are used in anesthesia to obtain adequate muscle
relaxation. Our aim is obtaining improvement in hospital budget by selecting ad-
equate neuromuscular blocking agents for short-term (under 60 minutes)pediatric
operations for hospital managements. METHODS: There is a basic investigation of
the duration to recovery time of atracurium and rocuronium administrations dur-
ing anesthesia induction in ASA I-II children. In order to evaluate the effect on
hospital budget, direct expenses were used. RESULTS: The mean time to reach
TOF75 in recovery with rocuronium and atracurium were calculated 38 and 51
minutes, respectively. In atracurium group, time to reach TOF75 was 51 minutes,
but operation time was 46 minutes(as rocuronium groups)and patients needed an
additional 5 minutes for recovery. During additional minutes, patients were kept in
the operation room(OR), thus preparation for the next patient was delayed. After
extubation of patients, to determine the period of preparation of an OR for the next
patient, a questionnaire was administered. This preparation was determined to be
14 minutes. These means, in the rocuronium and atrocurium groups one needs 60
minutes (4614) and 65 minutes (5114), respectively from the start of an opera-
tion to the start of next operation. In a pediatric surgery department, lower abdom-
inal and urogenital surgery unit income with rocuronium or atracurium are the
same but, rocuronium brings extra time for an average of 15 operations lasting
shorter than 1 hour. CONCLUSIONS: Study showed that if a hospital works with
100% performance and has no other problems (shortage of bed,personnel,etc), such
a hospital may perform, in a month, an extra 15 pediatric surgical operations less
than 1 hour can, by using rocuronium. Thus rocuronium may lead an additional
income of US$ 2436 per month for one OR. In other words, in short operations, using
rocuronium rather than atracurium may lead to savings which is 30-35% of total
cost.
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